<DOC>
	<DOCNO>NCT00003220</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bryostatin 1 treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Bryostatin 1 Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy bryostatin 1 administer 24 hour intravenous infusion every week 3 week 4 week course therapy patient colorectal cancer . II . Determine response duration , time progression , survival time patient population . III . Determine qualitative quantitative toxic effect bryostatin 1 schedule patient population . OUTLINE : Patients treat bryostatin 1 24 hour continuous intravenous infusion weekly 3 week follow 1 week rest . Courses repeat every 4 week absence unacceptable toxicity disease progression . Patients toxic effect completion first course therapy may dose bryostatin 1 escalate 1 dose level subsequent course . Patients follow response duration time treatment failure . PROJECTED ACCRUAL : A total 13-26 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colorectal cancer Unresectable disease Measurable disease No uncontrolled brain metastasis PATIENT CHARACTERISTICS : Age : Any age Performance status : SWOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Other : No active infection Not pregnant nursing Negative pregnancy test premenopausal woman Fertile patient must use effective contraception No concurrent uncontrolled systemic disorder No prior malignant disease within past year except situ carcinoma cervix curatively treat basal cell carcinoma skin No history allergy bryostatin 1 vehicle PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : Only one prior chemotherapy regimen adjuvant metastatic setting allow At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy ( except contraceptive , appetite stimulant replacement steroid ) Radiotherapy : At least 3 week since prior radiotherapy No concurrent radiation therapy No concurrent palliative radiation therapy site measurable disease Surgery : Not specify Other : At least 1 month since prior use investigational agent No concurrent use experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>